Validation of the age, neutrophil to lymphocyte ratio, C reactive protein score on 28 day mortality in the National COVID cohort collaborative.

ABSTRACT: Identifying patients at high mortality risk can improve outcomes in SARS-CoV-2 pneumonia (COVID-19). We validate a prognostic model for mortality in patients hospitalized with COVID-19 receiving dexamethasone using a retrospective multi-centered study. This is a retrospective cohort study using the National COVID Cohort Collaborative (NC3) including 9,708 adult patients admitted for COVID-19 who received dexamethasone within 24 h of admission and remained hospitalized for 72 h. Previous work from a single-center cohort informed selection of prognostic variables including Age, day 3 neutrophil-lymphocyte Ratio, and day 3 C-reactive protein level (ARC Score). Variables from the development cohort were analyzed in a training cohort, and the resulting model was tested in a validation cohort. A

SUBMITTER: Sines BJ 

PROVIDER: S-EPMC12318015 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature